Mankind Pharma Q2 FY27 Revenue Surges 17.3% to ₹4,338 Crore; PAT Up 37.7% to ₹716 Crore
Mankind Pharma reported Q2 FY27 revenue of ₹4,338 crore, a 17.3% YoY increase. PAT surged 37.7% to ₹716 crore. Domestic revenue grew 14.8% to ₹3,657 crore, exports up 32.7% to ₹681 crore. H1 FY27 revenue reached ₹8,368 crore, up 15.1% YoY. An earnings concall is scheduled for October 26, 2026.
Significant double-digit growth in revenue and profit, coupled with margin expansion, is a material development for investors and the company's market standing.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, along with improved margins and EPS, indicating a positive financial performance.
Mankind Pharma announced its financial results for the second quarter and half year ended September 30, 2026, reporting strong growth across key metrics.
For Q2 FY27, Revenue from Operations increased by 17.3% year-on-year to ₹4,338 crore. Domestic revenue grew by 14.8% to ₹3,657 crore, while exports rose by 32.7% to ₹681 crore. EBITDA margin improved by 210 basis points to 27.1%, and PAT margin saw an increase of 240 basis points to 16.5%. Diluted Earnings Per Share (EPS) stood at ₹17.2, up 38.9% year-on-year.
The company's domestic business, excluding Consumer Healthcare, grew by 15.9% driven by strong performance in chronic and acute therapeutic areas. Key brands like Pantakind, Pangraf, and Humog showed significant growth. The Consumer Healthcare business experienced softer growth impacting industry-wide offtake, though market share was gained in key brands like Manforce and Preganews.
International revenue surged by 33% in Q2 FY27, supported by growth in both Mankind and BSV International. Mankind launched one new product in the US during the quarter.
For H1 FY27, Revenue from Operations grew by 15.1% year-on-year to ₹8,368 crore. Domestic revenue increased by 12.7% to ₹7,082 crore, and exports were up 31.0% to ₹1,286 crore. EBITDA margin improved to 26.7%, and PAT margin to 15.4%. Diluted EPS for H1 FY27 was ₹30.9, up 34.6% year-on-year.
The company also announced its Earnings Concall scheduled for October 26, 2026, from 05:00 pm to 06:00 pm IST.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.